Cooper Companies, Inc. (COO)

The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia. Its CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage. This segment offers Paragard, a hormone-free intrauterine device; and fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals and clinics, and authorized resellers. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.

Symbol: COO
Exchange: Nasdaq
Sector: Healthcare
Industry: Medical Instruments & Supplies
Market cap: $10.82B
52 week range: 51.01 - 89.83

Valuation

Share price: $56.91 (close of 2026-10-02)
P/E (TTM): 19.36x
Price to book: 1.30x
Price to free cash flow: 15.96x
Enterprise value: $13.21B
Book value per share: $43.81

Price performance

Period	Change
1 day	-0.87%
5 days	+2.76%
1 month	-18.39%
3 months	-23.30%
6 months	-18.90%
Year to date	-30.56%
1 year	-17.66%
3 years	-27.01%
5 years	-45.39%
10 years	+27.00%
All time	+622.21%

Members of Congress who disclosed COO trades

Gilbert Ray Cisneros · Alan Armstrong · Robert Bresnahan

Super investors holding COO

Ken Griffin (Citadel) · Bill Nygren (Harris Associates LP) · Ray Dalio (Bridgewater Associates)

Profitability and growth

Return on equity: 4.55%
Return on invested capital: 4.62%
Return on assets: 3.02%
Return on capital employed: 6.05%
Gross margin: 65.54%
Net margin: 9.16%
EBITDA margin: 25.91%
Revenue growth: 5.06%
Net income growth: -4.44%
Free cash flow growth: 50.54%

Cash flow and balance sheet

Free cash flow yield (TTM): 6.27%
Current ratio: 1.22x
Net debt to EBITDA: 2.55x

Latest reported year

Period end: 2025-10-31
Fiscal year: 2025
Revenue: $4.09B
Cost of revenue: $1.41B
Gross profit: $2.68B
EBITDA: $1.06B
Net income: $374.90M
Earnings per share: $1.88
Research and development: $172.20M
Shares outstanding: 199.10M

Income statement by year

Period end	Revenue	Gross profit	Net income	EPS
2025-10-31	$4.09B	$2.68B	$374.90M	$1.88
2024-10-31	$3.90B	$2.60B	$392.30M	$1.97
2023-10-31	$3.59B	$2.36B	$294.20M	$1.49
2022-10-31	$3.31B	$2.14B	$385.80M	$1.95
2021-10-31	$2.92B	$1.96B	$2.94B	$14.95
2020-10-31	$2.43B	$1.53B	$238.40M	$1.21
2019-10-31	$2.65B	$1.76B	$466.70M	$2.36
2018-10-31	$2.53B	$1.63B	$139.90M	$0.71
2017-10-31	$2.14B	$1.37B	$372.90M	$1.91
2016-10-31	$1.97B	$1.17B	$273.90M	$1.41

Margins and returns by year

Period end	Gross margin	Net margin	Return on equity	Return on capital
2025-10-31	65.54%	9.16%	4.55%	4.62%
2024-10-31	66.64%	10.07%	4.85%	4.88%
2023-10-31	65.62%	8.19%	3.90%	4.14%
2022-10-31	64.67%	11.66%	5.38%	4.27%
2021-10-31	66.92%	100.76%	42.42%	5.88%
2020-10-31	63.14%	9.81%	6.23%	4.91%
2019-10-31	66.21%	17.59%	12.86%	9.99%
2018-10-31	64.45%	5.52%	4.23%	4.02%
2017-10-31	63.85%	17.43%	11.74%	9.63%
2016-10-31	59.65%	13.93%	10.16%	7.75%

Cash and debt by year

Period end	Cash	Debt
2025-10-31	$110.60M	$2.46B
2024-10-31	$107.60M	$2.55B
2023-10-31	$120.80M	$2.52B
2022-10-31	$138.20M	$2.35B
2021-10-31	$95.90M	$1.40B
2020-10-31	$115.90M	$1.38B
2019-10-31	$89.00M	$1.26B
2018-10-31	$77.70M	$1.99B
2017-10-31	$88.80M	$1.15B
2016-10-31	$100.80M	$1.11B

Free cash flow by year

Period end	Free cash flow	Stock-based compensation
2025-10-31	$433.70M	$70.50M
2024-10-31	$288.10M	$75.10M
2023-10-31	$215.00M	$62.10M
2022-10-31	$450.40M	$54.20M
2021-10-31	$524.20M	$43.80M
2020-10-31	$176.20M	$37.60M
2019-10-31	$421.10M	$35.10M
2018-10-31	$475.30M	$43.20M
2017-10-31	$466.40M	$37.20M
2016-10-31	$357.00M	$29.90M

Dividend history

Most recent payment: 2023-07-26

Payment date	Dividend per share
2023-07-26	$0.03
2023-01-20	$0.03
2022-07-26	$0.03
2022-01-20	$0.03
2021-07-26	$0.03
2021-01-21	$0.03
2020-07-22	$0.03
2020-01-22	$0.03

Investor relations

Past earnings dates

Reported	Fiscal period	EPS estimate
2026-09-09	Jul/2026	$1.11
2026-06-04	Apr/2026	$1.10
2026-03-05	Jan/2026	$1.03
2025-12-04	Oct/2025	$1.11
2025-08-27	Jul/2025	$1.07
2025-05-29	Apr/2025	$0.93
2025-03-06	Jan/2025	$0.92
2024-12-05	Oct/2024	$1.00

Filings and sources

Company website: coopercos.com
SEC filings: 10-K, 10-Q and 8-K on EDGAR
Earnings calendar: All upcoming reports

Similar companies

Avantor, Inc. (AVTR) · Repligen Corp (RGEN) · Align Technology Inc (ALGN) · Baxter International Inc (BAX) · Teleflex Inc (TFX) · Solventum Corp (SOLV) · West Pharmaceutical Services Inc (WST) · Medline Inc. (MDLN)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades